1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NCI SBIR/STTR Omnibus Grant Solicitations is sponsored by National Cancer Institute (NCI) (part of NIH). The NCI offers SBIR and STTR grant opportunities for small businesses engaged in research and development within the mission of the National Institutes of Health.
NCI's research areas of interest include therapeutics, in vitro and in vivo diagnostics, imaging technologies, devices for cancer therapy, tools for cancer biology research, technologies and agents for cancer prevention, technologies for cancer control, and digital health.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses with an investigator-defined scope within the NIH mission and NCI's research areas of interest. Confirm the full requirements in the official notice before applying.
The current listing shows NCI budget guideline: Phase I up to $700,000; Phase II up to $2,500,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for NCI SBIR/STTR Omnibus Grant Solicitations are due January 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NCI SBIR/STTR Omnibus Grant Solicitations is funded by National Cancer Institute (NCI) (part of NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NIH SBIR/STTR Omnibus Grant Solicitations (NCI) is a grant program from the National Cancer Institute, part of the National Institutes of Health, that funds investigator-initiated small business innovation research across a broad spectrum of health and cancer research topic areas. The program encompassed both Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) mechanisms through Phase I (R43/R41) and Phase II (R44/R42) awards, with options for both clinical trial and non-clinical trial research. Eligible applicants are U.S. small business concerns with research capabilities and technological expertise relevant to NIH's mission, including those majority-owned by venture capital operating companies, hedge funds, or private equity firms. Note that the legislative authority for the SBIR/STTR programs expired on October 1, 2025, and NIH currently has no active solicitations.
NCI SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI) (part of NIH). This NOFO specifically solicits SBIR grant applications from small business concerns to support later-stage research and development (Phase IIB) for projects previously funded under SBIR or STTR Phase II awards from any federal agency.
PAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleThe April 14 SBIR/STTR reauthorization restarted NIH's small-business pipeline after the shutdown, but the real signal is the sequencing of the new Small Business 101 webinars: program overview June 9, budget July 14, foreign risk August 18.
Read article